

S.S.D. Immunobiologia dei Tumori Umani – Pubblicazioni selezionate (2014-2018).

1. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-Label, single-arm, phase II study. *J Clin Oncol*. 2018 Oct 20;JCO1801148. doi: 10.1200/JCO.18.01148.
2. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Prunerì G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. *Clin Cancer Res*. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-1390.
3. Satta A, Mezzanzanica D, Caroli F, Frigerio B, Di Nicola M, Kontermann RE, Iacovelli F, Desideri A, Anichini A, Canevari S, Gianni AM, Figini M. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. *MAbs*. 2018 Oct;10(7):1084-1097. doi: 10.1080/19420862.2018.1494105.
4. Anichini A, Tassi E, Grazia G, Mortarini R. The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. *Cancer Immunol Immunother*. 2018 Jun;67(6):1011-1022. doi: 10.1007/s00262-018-2147-7.
5. Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M. Innovative therapy, monoclonal antibodies and beyond. *Cytokine Growth Factor Rev*. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002.
6. Necchi A, Anichini A, Sonpavde G. Of chemoimmunotherapy sequences and delayed disease-modifying activity in advanced urothelial carcinoma: *Vetus Fit Novum*. *Eur Urol*. 2018 Feb;73(2):153-155. doi: 10.1016/j.eururo.2017.09.012.
7. Talerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA, Carbone E. IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. *Oncoimmunology*. 2016 Dec 7;6(2):e1261242. doi: 10.1080/2162402X.2016.1261242.
8. Tassi E, Grazia G, Vegetti C, Bersani I, Bertolini G, Molla A, Baldassari P, Andriani F, Roz L, Sozzi G, Pastorino U, Mortarini R, Anichini A. Early effector T lymphocytes coexpress multiple inhibitory receptors in primary non-small cell lung cancer. *Cancer Res*. 2017 Feb 15;77(4):851-861. doi: 10.1158/0008-5472.CAN-16-1387.
9. Necchi A, Anichini A, Raggi D, Giannatempo P, Magazzù D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM. Brentuximab vedotin in CD30-expressing germ cell tumors after chemotherapy failure. *Clin Genitourin Cancer*. 2016 Aug;14(4):261-264.e4. doi: 10.1016/j.clgc.2016.03.020.
10. Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. *Oncotarget*. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600.
11. Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. *Eur J Immunol*. 2016 Feb;46(2):409-19. doi: 10.1002/eji.201445289. Epub 2015 Dec 20.
12. Perotti V, Baldassari P, Molla A, Vegetti C, Bersani I, Maurichi A, Santinami M, Anichini A, Mortarini R. NFATc2 is an intrinsic regulator of melanoma dedifferentiation. *Oncogene*. 2016 Jun 2;35(22):2862-72. doi: 10.1038/nc.2015.355.
13. Dugo M, Nicolini G, Tragni G, Bersani I, Tomassetti A, Colonna V, Del Vecchio M, De Braud F, Canevari S, Anichini A, Sensi M. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. *Oncotarget*. 2015 Mar 10;6(7):5118-33.
14. Loria R, Bon G, Perotti V, Gallo E, Bersani I, Baldassari P, Porru M, Leonetti C, Di Carlo S, Visca P, Brizzi MF, Anichini A, Mortarini R, Falcioni R. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. *Oncotarget*. 2015 Feb 20;6(5):2779-93.
15. Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Talerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Kärre K, Carbone E. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. *Nat Commun*. 2014 Dec 4;5:5639. doi: 10.1038/ncomms6639.
16. Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. *Cell Death Dis*. 2014 Oct 2;5:e1434. doi: 10.1038/cddis.2014.410.
17. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. *Clin Cancer Res*. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770.
18. Tringali C, Silvestri I, Testa F, Baldassari P, Anastasia L, Mortarini R, Anichini A, López-Requena A, Tettamanti G, Venerando B. Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. *BMC Cancer*. 2014 Aug 1;14:560. doi: 10.1186/1471-2407-14-560.
19. Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M. Prediction of survival in patients with thin melanoma: results from a multi-institution study. *J Clin Oncol*. 2014 Aug 10;32(23):2479-85. doi: 10.1200/JCO.2013.54.2340.
20. Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. *Leukemia*. 2014 Sep;28(9):1861-71. doi: 10.1038/leu.2014.81.